View in EDS

A Rare Case of Dapagliflozin-Induced Hepatic Toxicity

Saved in:
Bibliographic Details
Title: A Rare Case of Dapagliflozin-Induced Hepatic Toxicity
Authors: Fernandes,Catarina Borges, Ramalho,Paulo Torres
Source: Medicina Interna v.31 n.3 2024
Publisher Information: Sociedade Portuguesa de Medicina Interna, 2024.
Publication Year: 2024
Subject Terms: Chemical and Drug Induced Liver Injury, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors/adverse effects
Description: Drug-induced liver injury is a challenging clinical condition in terms of both diagnosis and treatment. It presents a wide range of clinical manifestations, and identification of the implicated substance is crucial. Several adverse effects have been described in association with dapagliflozin, but not liver enzyme elevation. The authors present the case of a 71-year-old diabetic woman who developed gastrointestinal symptoms one month after increasing the dose of dapagliflozin. Liver en-zyme elevation was observed, without evidence of obstructive causes on imaging exams. Other causes of liver disease were excluded, and liver biopsy favored a toxic/drug etiology. Liver enzyme normalization was observed after discontinuation of dapagliflozin. Liver injury associated with sodium-glucose co-transporter 2 inhibitors is very rare, and the authors aim to raise awareness about the potential hepatotoxic effects of dapagliflozin, highlighting the importance of early diagnosis and appropriate treatment.
Document Type: Report
File Description: text/html
Language: English
Access URL: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2024000400039
Accession Number: edsair.od.......616..660c635fb8cbadbc727aafaee84cf18a
Database: OpenAIRE
Description
Abstract:Drug-induced liver injury is a challenging clinical condition in terms of both diagnosis and treatment. It presents a wide range of clinical manifestations, and identification of the implicated substance is crucial. Several adverse effects have been described in association with dapagliflozin, but not liver enzyme elevation. The authors present the case of a 71-year-old diabetic woman who developed gastrointestinal symptoms one month after increasing the dose of dapagliflozin. Liver en-zyme elevation was observed, without evidence of obstructive causes on imaging exams. Other causes of liver disease were excluded, and liver biopsy favored a toxic/drug etiology. Liver enzyme normalization was observed after discontinuation of dapagliflozin. Liver injury associated with sodium-glucose co-transporter 2 inhibitors is very rare, and the authors aim to raise awareness about the potential hepatotoxic effects of dapagliflozin, highlighting the importance of early diagnosis and appropriate treatment.